

Plasma membrane FGFR1 fusions auto- phosphorylate

Grose, RP., Rothfels, K.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of [Creative Commons Attribution 4.0 International \(CC BY 4.0\) License](#). For more information see our [license](#).

28/04/2024

Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

Literature references

- Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics*, 18, 142. [↗](#)
- Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics*, 33, 3461-3467. [↗](#)
- Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res*, 46, D649-D655. [↗](#)
- Fabregat, A., Korninger, F., Viteri, G., Sidiropoulos, K., Marin-Garcia, P., Ping, P. et al. (2018). Reactome graph database: Efficient access to complex pathway data. *PLoS computational biology*, 14, e1005968. [↗](#)

Reactome database release: 88

This document contains 1 reaction ([see Table of Contents](#))


Plasma membrane FGFR1 fusions autophosphorylate [↗](#)

Stable identifier: R-HSA-8853325

Type: transition

Compartments: plasma membrane

Diseases: cancer



Although it hasn't been directly demonstrated in all cases, the ability to promote transformation and anchorage independent growth suggests these fusions undergo autophosphorylation similar to WT FGFR1 proteins. Indeed, active kinase activity has been demonstrated for the the ERLIN2-FGFR1 fusion identified in breast cancer (Singh et al, 2012; Wu et al, 2013; Wang et al, 2014; reviewed in Parker et al, 2014)

Literature references

- Kalyana-Sundaram, S., Chinnaiyan, AM., Wang, R., Tomlins, SA., Ateeq, B., Cao, X. et al. (2013). Identification of targetable FGFR gene fusions in diverse cancers. *Cancer Discov*, 3, 636-47. [↗](#)
- Gao, Z., Sullivan, R., Niola, F., Guha, A., Zoppoli, P., Castano, A. et al. (2012). Transforming fusions of FGFR and TACC genes in human glioblastoma. *Science*, 337, 1231-5. [↗](#)
- Luo, X., Sun, Y., Ye, T., Zhang, J., Shen, L., Pan, B. et al. (2014). FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. *Clin. Cancer Res.*, 20, 4107-14. [↗](#)
- Parker, BC., Zhang, W., Annala, M., Engels, M. (2014). Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours. *J. Pathol.*, 232, 4-15. [↗](#)

Editions

2016-01-09	Authored, Edited	Rothfels, K.
2016-01-25	Reviewed	Grose, RP.